Vertex Pharmaceuticals has entered a definitive agreement to acquire ViroChem Pharma in a stock and cash transaction worth $376 million. The acquisition adds two polymerase inhibitors to Vertex’s hepatitis C virus (HCV) drug development portfolio, which includes the HCV protease inhibitor telaprevir. With the addition of these compounds, Vertex will pursue new combinations of Specifically Targeted Antiviral Therapies for hepatitis C (STAT-Cs) for the treatment of HCV infection. ViroChem’s HC...